| Filed On | Filing |
|---|---|
| 08 Aug 2025 |
8-K/A: Results of Operations and Financial Condition
Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025. |
| 14 Apr 2022 |
8-K/A: Other Events
On April 12, 2022, the U.S. Food and Drug Administration granted aTyr Pharma, Inc. orphan drug designation for its lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis (SSc, also known as scleroderma). |
Loading...